NCT03317236View on ClinicalTrials.gov

Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

October 1, 2017

Study Completion Date

October 1, 2017

Conditions
Healthy
Interventions
DRUG

Quetiapine

A fixed 50 mg exteded release formulation.

Trial Locations (1)

3102

DominguezLab, Paraná

Sponsors
All Listed Sponsors
collaborator

DominguezLab S.R.L.

UNKNOWN

lead

Laboratorio Elea Phoenix S.A.

INDUSTRY